Shots:
- Imagene & Tempus AI have collaborated to advance lung cancer diagnostics by enhancing biomarker prediction, integrating AI tools into clinical workflows, & allowing commercial access to diagnostic solutions
- Collaboration will integrate Imagene’s AI multi-gene panel for rapid NSCLC biomarker prediction from biopsy images with Tempus’ clinical reach & real-world data, creating a unified AI-powered biomarker prediction panel for nationwide commercialization
- The panel will improve biomarker precision & personalized care by providing rapid, accurate NSCLC target predictions (EGFR, ALK, MET, BRAF, HER2, RET, & ROS1) via Tempus’ test portfolio while refining Imagene’s AI models with real-world data
Ref: Accessnewswire | Image: Imagene & Tempus
Related News:- Avacta Therapeutics Collaborates with Tempus AI to Commence AI-Driven Drug Development in Oncology
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
